TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00511134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
Study: NCT00767806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 60 mg orally once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily orally for 12 weeks
Study: NCT03226834

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MUSIC CARE
Description: Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PERSONAL PLAY-LIST
Description: Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
Study: NCT01983085

Intervention type: DEVICE
Group type: OTHER
Intervention: NOx dressing
Description: The NOx dressing should be changed at least every 2 days.

Intervention type: DEVICE
Group type: OTHER
Intervention: NOx dressing
Description: The NOx dressing should be changed at least every 2 days.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care
Description: Dressing changed as per normal clinical practice

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care
Description: Dressing changed as per normal clinical practice
Study: NCT00742183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex
Description: Mepilex Ag - dressing changes every 5-7 days, more frequently if needed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silvadene
Description: Silvadene - dressing changes every day, more frequently if needed
Study: NCT01590407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-002200
Description: ALS-002200

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00207142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + 2 NRTIs
Description: Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + Ritonavir + 2 NRTIs
Description: Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)

Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir + Ritonavir + 2 NRTIs
Description: Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
Study: NCT03742141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative Video Laryngoscopy
Description: The IOVL is a disposable, otherwise standard fiberoptic laryngoscope that is inserted alongside the endotracheal tube following intubation for surgical procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: 0.004mg/kg as per routine prior to intubation
Study: NCT00375843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
Study: NCT02961699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpose ® RT System
Description: adipose-derived stem cell therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: debridement/dressing of wound
Description: standard of care debridement and wound dressing
Study: NCT01192152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: Tablets, Oral, 5 mg, once daily, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage XR
Description: Tablets, Oral, 500 mg, once daily, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin + metformin XR (FDC tablet)
Description: Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin + metformin XR (FDC tablet)
Description: Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
Study: NCT00850954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00649337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography
Description: AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.~The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed.
Study: NCT01680315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low calorie yogurt
Description: all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low calorie yogurt
Description: all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high calorie yogurt
Description: all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high calorie yogurt
Description: all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
Study: NCT02161588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily oral administration as tablets.
Study: NCT02632630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acids w/Electrolytes in Dextrose
Description: Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure product
Description: Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid solutions
Description: Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral nutritional supplementation
Description: Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
Study: NCT01072058

Intervention type: DRUG
Group type: OTHER
Intervention: TNF blockers (infliximab, adalimumab, etanercept)
Description: Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
Study: NCT01816165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
Study: NCT04595825

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - intravenous infusion
Study: NCT03801070

Intervention type: PROCEDURE
Intervention: endoscopic drainage of walled off pancreatic necrosis
Description: transmural drainage and mechanical debridement of solid debris (necrosectomy)

Intervention type: PROCEDURE
Intervention: endoscopic drainage of walled off pancreatic necrosis
Description: transmural drainage and mechanical debridement of solid debris (necrosectomy)
Study: NCT01757795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8203
Description: SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be intravenously administered
Study: NCT01484691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
Study: NCT01418365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole + MMX Mesalazine/mesalamine placebo
Description: Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole + MMX Mesalazine/mesalamine
Description: Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
Study: NCT00830726

Intervention type: DRUG
Intervention: Pharmacologic and mechanical heart failure treatment
Description: Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
Study: NCT03675061

Intervention type: OTHER
Group type: OTHER
Intervention: Current care
Description: Tocolysis and a complete corticosteroid treatment.

Intervention type: DEVICE
Group type: OTHER
Intervention: PartoSure Test negative
Description: Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .

Intervention type: DEVICE
Group type: OTHER
Intervention: PartoSure Test positive
Description: Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
Study: NCT02463370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: suprazygomatic maxillary area infiltration
Description: Local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas.
Study: NCT02375672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion
Study: NCT04578847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Initial dose - 400 mg daily. If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
Study: NCT04944589

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROOT CANAL TREATMENT
Description: Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROOT CANAL TREATMENT
Description: Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.
Study: NCT02463370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-suprazygomatic maxillary area placebo
Description: The remaining injections at supratrochlear area, medial to the medial canthus, nasal still and anterior septum are placebo (saline)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-suprazygomatic maxillary area infiltration
Description: Local anesthetic infiltration in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: suprazygomatic maxillary area placebo
Description: The remaining maxillary injection is placebo.
Study: NCT04716647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ayurveda
Description: Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.
Study: NCT04578847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Initial dose - 300 or 400 mg twice daily. If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Initial dose 100 or 140 mg daily. If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Initial dose 500 mg daily. If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.
Study: NCT04594850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram-ED
Description: Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.
Study: NCT00058825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
Study: NCT01849965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSC127
Description: DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
Study: NCT00830726

Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.

Intervention type: PROCEDURE
Intervention: Revascularisation in Acute Coronary Syndrome
Description: Standard percutaneous or surgical revascularisation in ACS.

Intervention type: PROCEDURE
Intervention: Revascularisation in chronic stable angina pectoris
Description: Standard percutaneous or surgical revascularisation
Study: NCT02549391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRN1493
Description: Oral administration
Study: NCT01849965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vehicle gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care gel, Aquasite
Study: NCT01593397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and Fentanyl administration
Description: Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
Study: NCT04523207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
Study: NCT00058825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -5 to Day -2: Fludarabine 30 mg/m2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Day 0: Donor stem cells infused.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506 (Tacrolimus) or Cyclosporine
Description: Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
Study: NCT01531699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT005 Ophthalmic Prep Solution
Description: single application for up to 6 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline control
Description: single application for up to 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine ophthalmic prep solution
Description: single application for up to 6 hours
Study: NCT03337204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted self-monitoring
Description: Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology-assisted self-monitoring
Description: Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
Study: NCT04552366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV
Description: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV
Description: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Study: NCT03337204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop and Peer Mentoring
Description: Participants receive a 3-hour Engaged4Life Workshop (psychoeducation + goal setting) and one-on-one peer mentoring via phone 2X/week for 3 weeks.
Study: NCT03439800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental and Physical Practice
Description: 1. Subjects will see a video of the typical gait and will attempt to analyze the sequence of the gait cycle.~2. They will imagine themselves walking in the first-person perspective (kinesthetic) using the gait of the non-pathological pattern during 2 minutes.~3. From the 1st to 4th session, the subjects will perform gait with corrections identified in previously in the video for 2 minutes.~4. From 5th to 8th session: the subjects will do the protocol already described, however, the imagined gait will be in an environment with obstacles, also for 2 minutes. They will continue with the physical practice of the gait with obstacles.~5. From 9th to final training session: both mental and physical practice of the dual task gait.
Study: NCT04523207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Participants will receive ADT intramuscular or subcutaneously during the main study.
Study: NCT03439800

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Practice
Description: 1. Subjects will see a video about PD which does not mention physiotherapy treatments related to gait and they will explain their understanding about the theme.~2. Then, the patients will make the physical gait protocol. Patients will be invited to perform the gait, in flat and firm ground with a length of 60 meters. The execution will be carried out for 10 minutes.~3. From the 5th to 8th session, the subjects will do the physical practice of the gait with obstacles (which will be: going through 2 cones zigzag, going up and down 1 step, going through a narrow door, going up and down 1 ramp, going over 1 box of shoes, climbing a ramp, going down 1 step) for 2 minutes.~4. From the 9th to the final training session, the subjects will do physical practice of the dual task gait.
Study: NCT02320045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (Exenatide in osmotic mini pump)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (Exenatide in osmotic mini pump)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (Exenatide in osmotic mini pump)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (Exenatide in osmotic mini pump)
Study: NCT01636700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol 2mg/kg
Description: 2mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: saline solution- 1 dose